GMPR

Summary

GMPR (guanosine monophosphate reductase, HGNC:4376) is a protein-coding gene on chromosome 6p22.3, encoding GMP reductase 1 (P36959). Catalyzes the irreversible NADPH-dependent deamination of GMP to IMP.

This gene encodes an enzyme that catalyzes the irreversible and NADPH-dependent reductive deamination of GMP to IMP. The protein also functions in the re-utilization of free intracellular bases and purine nucleosides.

Source: NCBI Gene 2766 — RefSeq curated summary.

At a glance

• GWAS associations: 53
• Clinical variants (ClinVar): 80 total — 1 likely-pathogenic
• MANE Select transcript: NM_006877

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4376
Approved symbol	GMPR
Name	guanosine monophosphate reductase
Location	6p22.3
Locus type	gene with protein product
Status	Approved
Aliases	GMPR1, hGMPR-I
Ensembl gene	ENSG00000137198
Ensembl biotype	protein_coding
OMIM	139265
Entrez	2766

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 10 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000259727, ENST00000540478, ENST00000543191, ENST00000544145, ENST00000864757, ENST00000864758, ENST00000864759, ENST00000864760, ENST00000864761, ENST00000967431, ENST00000967432, ENST00000967433, ENST00000967434

RefSeq mRNA: 1 — MANE Select: NM_006877 NM_006877

CCDS: CCDS4537

Canonical transcript exons

ENST00000259727 — 9 exons

Exon	Start	End
ENSE00000928728	16278784	16278890
ENSE00000928730	16254562	16254735
ENSE00000928731	16250284	16250367
ENSE00000928732	16246842	16246961
ENSE00000928733	16238587	16238780
ENSE00001790043	16274415	16274496
ENSE00002206969	16295006	16295549
ENSE00003512555	16290462	16290621
ENSE00003523290	16285793	16285835

Expression profiles

Bgee: expression breadth ubiquitous, 249 present calls, max score 98.90.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.8152 / max 321.6295, expressed in 1389 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
66090	10.8152	1389
66092	1.6579	730
66089	0.2143	72
66095	0.1188	50

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gastrocnemius	UBERON:0001388	98.90	gold quality
hindlimb stylopod muscle	UBERON:0004252	98.66	gold quality
apex of heart	UBERON:0002098	98.51	gold quality
muscle of leg	UBERON:0001383	98.19	gold quality
right uterine tube	UBERON:0001302	98.11	gold quality
muscle organ	UBERON:0001630	97.60	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	97.07	gold quality
heart left ventricle	UBERON:0002084	96.62	gold quality
skeletal muscle tissue	UBERON:0001134	96.29	gold quality
cardiac ventricle	UBERON:0002082	96.23	gold quality
right testis	UBERON:0004534	96.10	gold quality
vastus lateralis	UBERON:0001379	96.02	gold quality
right atrium auricular region	UBERON:0006631	96.01	gold quality
quadriceps femoris	UBERON:0001377	95.92	gold quality
left testis	UBERON:0004533	95.82	gold quality
biceps brachii	UBERON:0001507	95.54	gold quality
deltoid	UBERON:0001476	95.34	gold quality
triceps brachii	UBERON:0001509	95.30	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	94.63	gold quality
cardiac atrium	UBERON:0002081	94.15	gold quality
heart	UBERON:0000948	94.08	gold quality
gluteal muscle	UBERON:0002000	93.81	gold quality
testis	UBERON:0000473	93.66	gold quality
tibialis anterior	UBERON:0001385	93.64	silver quality
left ovary	UBERON:0002119	93.45	gold quality
diaphragm	UBERON:0001103	93.38	gold quality
monocyte	CL:0000576	93.33	gold quality
ascending aorta	UBERON:0001496	93.10	gold quality
thoracic aorta	UBERON:0001515	93.05	gold quality
right ovary	UBERON:0002118	92.82	gold quality

Single-cell (SCXA)

Detected in 16 experiment(s), a significant marker in 14.

Experiment	Marker?	Max mean expression
E-ENAD-20	yes	372.94
E-GEOD-75367	yes	366.97
E-MTAB-7052	yes	44.51
E-CURD-112	yes	32.09
E-HCAD-4	yes	30.45
E-HCAD-6	yes	26.85
E-MTAB-9221	yes	23.10
E-CURD-122	yes	20.62
E-MTAB-9067	yes	10.67
E-MTAB-6701	yes	10.53
E-HCAD-9	yes	9.01
E-HCAD-1	yes	6.18
E-MTAB-9467	yes	3.32
E-MTAB-6075	no	155.32
E-MTAB-5061	no	3.76

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

28 targeting GMPR, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-18A-5P	99.29	71.05	806
HSA-MIR-18B-5P	99.29	71.05	806
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-1264	99.25	66.81	1317
HSA-MIR-4528	99.18	69.77	1936
HSA-MIR-7109-5P	99.18	66.13	1057
HSA-MIR-4735-3P	99.14	69.85	777
HSA-MIR-6760-5P	98.87	66.73	1515
HSA-MIR-760	98.81	66.65	1392
HSA-MIR-655-5P	98.74	65.93	888
HSA-MIR-214-3P	98.71	68.12	2128
HSA-MIR-6887-5P	98.56	68.49	1295
HSA-MIR-6795-5P	98.52	68.51	1277
HSA-MIR-4722-5P	98.46	66.34	1611
HSA-MIR-4768-3P	98.16	66.02	2330
HSA-MIR-5681A	97.99	67.17	1658
HSA-MIR-296-5P	97.61	64.02	851

Literature-anchored findings (GeneRIF, showing 2)

• GMPR as a suppressor of melanoma invasion is downregulated at the early invasive stages of melanoma progression and whose activity inhibits melanoma cell invasion by depleting intracellular GTP pools. (PMID:24139804)
• New biochemical insights into the dynamics of water molecules at the GMP or IMP binding site of human GMPR enzyme: A molecular dynamics study. (PMID:34368983)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	gmpr	ENSDARG00000016160
mus_musculus	Gmpr	ENSMUSG00000000253
rattus_norvegicus	Gmpr	ENSRNOG00000017250
caenorhabditis_elegans		WBGENE00017984

Paralogs (3): GMPR2 (ENSG00000100938), IMPDH1 (ENSG00000106348), IMPDH2 (ENSG00000178035)

Protein

Protein identifiers

GMP reductase 1 — P36959 (reviewed: P36959)

Alternative names: Guanosine 5’-monophosphate oxidoreductase 1

All UniProt accessions (1): P36959

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the irreversible NADPH-dependent deamination of GMP to IMP. It functions in the conversion of nucleobase, nucleoside and nucleotide derivatives of G to A nucleotides, and in maintaining the intracellular balance of A and G nucleotides.

Subunit / interactions. Homotetramer.

Polymorphism. At least two different alleles are known.

Similarity. Belongs to the IMPDH/GMPR family. GuaC type 1 subfamily.

RefSeq proteins (1): NP_006868* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001093	IMP_DH_GMPRt	Domain
IPR005993	GMPR	Family
IPR013785	Aldolase_TIM	Homologous_superfamily
IPR015875	IMP_DH/GMP_Rdtase_CS	Conserved_site
IPR050139	GMP_reductase	Family

Pfam: PF00478

Enzyme classification (BRENDA):

• EC 1.7.1.7 — GMP reductase (BRENDA: 18 organisms, 39 substrates, 64 inhibitors, 37 Km, 4 kcat entries)

Substrate kinetics (BRENDA)

7 substrates with measured Km, best-characterized 7. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
GMP	0.0014–0.38	15
NADPH	0.0085–0.12	12
NADP+	0.05–0.42	3
IMP	0.023–1.1	2
DGMP	0.015	1
DIMP	0.14	1
GUANOSINE 5’-PHOSPHATE	0.0055	1

Catalyzed reactions (Rhea), 1 shown:

• IMP + NH4(+) + NADP(+) = GMP + NADPH + 2 H(+) (RHEA:17185)

UniProt features (57 total): strand 17, helix 17, binding site 15, turn 3, active site 2, sequence variant 2, chain 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
2BLE	X-RAY DIFFRACTION	1.9
2BWG	X-RAY DIFFRACTION	2.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P36959-F1	97.04	0.95

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 186 (thioimidate intermediate); 188 (proton donor/acceptor)

Ligand- & substrate-binding residues (15): 189; 219–221; 242–243; 268–270; 269 (in other chain); 285–286 (in other chain); 286–290; 314–317; 26–27; 78 (in other chain); 129–131 (in other chain); 180–181 (in other chain) …

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-74217	Purine salvage
R-HSA-9854909	Regulation of MITF-M dependent genes involved in invasion

MSigDB gene sets: 208 (showing top): VERHAAK_AML_WITH_NPM1_MUTATED_DN, SHEPARD_BMYB_MORPHOLINO_UP, GOBP_RESPONSE_TO_COLD, MODULE_45, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, MODULE_16, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, GOBP_NUCLEOBASE_METABOLIC_PROCESS, BLALOCK_ALZHEIMERS_DISEASE_UP, MCBRYAN_PUBERTAL_BREAST_3_4WK_UP, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP, MODULE_157, CCCNNNNNNAAGWT_UNKNOWN

GO Biological Process (5): purine nucleobase metabolic process (GO:0006144), purine nucleotide metabolic process (GO:0006163), response to cold (GO:0009409), purine nucleotide biosynthetic process (GO:0006164), nucleotide metabolic process (GO:0009117)

GO Molecular Function (6): GMP reductase activity (GO:0003920), metal ion binding (GO:0046872), catalytic activity (GO:0003824), IMP dehydrogenase activity (GO:0003938), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (2): cytosol (GO:0005829), GMP reductase complex (GO:1902560)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Nucleotide salvage	1
MITF-M-dependent gene expression	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
purine-containing compound metabolic process	2
nucleobase metabolic process	1
nucleotide metabolic process	1
response to stress	1
response to temperature stimulus	1
purine nucleotide metabolic process	1
nucleotide biosynthetic process	1
purine-containing compound biosynthetic process	1
nucleoside phosphate metabolic process	1
oxidoreductase activity, acting on other nitrogenous compounds as donors, with NAD or NADP as acceptor	1
cation binding	1
molecular_function	1
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	1
binding	1
catalytic activity	1
cytoplasm	1
cellular anatomical structure	1
oxidoreductase complex	1

Protein interactions and networks

STRING

2170 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GMPR	GMPS	P49915	667
GMPR	ADSL	P30566	588
GMPR	GDA	Q9Y2T3	564
GMPR	APRT	P07741	521
GMPR	ADSS2	P30520	489
GMPR	AMPD3	Q01432	477
GMPR	MX1	P20591	451
GMPR	GNPDA1	P46926	449
GMPR	AMPD2	Q01433	448
GMPR	MGST3	O14880	435
GMPR	ARHGAP6	O43182	425
GMPR	ORMDL2	Q53FV1	420
GMPR	CADM3	Q8N126	420
GMPR	DCAF12	Q5T6F0	411
GMPR	ATIC	P31939	405

IntAct

6 interactions, top by confidence:

A	B	Type	Score
GMPR2	GMPR	psi-mi:“MI:0914”(association)	0.500
GMPR	GMPR2	psi-mi:“MI:0915”(physical association)	0.500
GMPR	GMPR	psi-mi:“MI:0915”(physical association)	0.370
GMPR2	GMPR	psi-mi:“MI:0914”(association)	0.350
U2AF1	MED19	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (11): GMPR (Two-hybrid), GMPR (Affinity Capture-MS), GMPR (Affinity Capture-MS), GMPR (Positive Genetic), GMPR (Affinity Capture-MS), GMPR2 (Affinity Capture-MS), PRPS1 (Co-fractionation), ATXN2 (Co-fractionation), NOSIP (Co-fractionation), GMPR (Affinity Capture-MS), GMPR (Affinity Capture-MS)

ESM2 similar proteins: A3KN12, O88958, P21265, P21343, P30566, P36959, P38024, P50554, P50990, P54822, P61922, P78371, P80147, P80314, P80404, P82197, Q04447, Q0II59, Q259G4, Q2KIG0, Q3ZBF0, Q3ZBH0, Q3ZCI9, Q41141, Q4R4U1, Q4R5J0, Q4R5Y2, Q4R6F8, Q5E982, Q5R5F8, Q5RAP1, Q5XIM9, Q5ZMA6, Q64422, Q6EE31, Q6IA69, Q711T7, Q7XPW5, Q7ZV22, Q812E8

Diamond homologs: A0A0B5L585, A0JNA3, A8HAF6, A9A5Y7, B0TQE1, B0UXP9, B1L5U5, B5EUG3, D3ZLZ7, E9BDA8, E9PU28, F1DBB2, F6S675, F7CYY5, O00086, O14344, O42831, O50316, O58045, O67820, P0ADG7, P0ADG8, P0ADG9, P0C0H6, P0C0H7, P0DB88, P0DB89, P12268, P12269, P20839, P21620, P21879, P24547, P31002, P36959, P38697, P39567, P42851, P44334, P47996

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
GMPR	“down-regulates quantity”	“guanosine 5’-monophosphate(2-)”	“chemical modification”
GMPR	“down-regulates quantity”	NADPH(4-)	“chemical modification”
GMPR	“down-regulates quantity”	hydron	“chemical modification”
GMPR	“up-regulates quantity”	IMP	“chemical modification”
GMPR	“up-regulates quantity”	ammonium	“chemical modification”
GMPR	“up-regulates quantity”	NADP(3-)	“chemical modification”

Disease & clinical

Clinical variants and AI predictions

ClinVar

80 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	55
Likely benign	1
Benign	5

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1527220	GRCh37/hg19 6p24.3-22.3(chr6:8269414-17402660)	Likely pathogenic

SpliceAI

2022 predictions. Top by Δscore:

Variant	Effect	Δscore
6:16238733:G:GT	donor_gain	1.0000
6:16238795:G:GT	donor_gain	1.0000
6:16246832:T:TA	acceptor_gain	1.0000
6:16246833:G:A	acceptor_gain	1.0000
6:16246839:CA:C	acceptor_loss	1.0000
6:16246840:A:AG	acceptor_gain	1.0000
6:16246840:AG:A	acceptor_gain	1.0000
6:16246840:AGGT:A	acceptor_gain	1.0000
6:16246840:AGGTG:A	acceptor_gain	1.0000
6:16246841:G:GT	acceptor_gain	1.0000
6:16246841:GG:G	acceptor_gain	1.0000
6:16246841:GGT:G	acceptor_gain	1.0000
6:16246841:GGTG:G	acceptor_gain	1.0000
6:16246841:GGTGG:G	acceptor_gain	1.0000
6:16246960:AGGTG:A	donor_loss	1.0000
6:16246961:GGTGA:G	donor_loss	1.0000
6:16246963:T:G	donor_loss	1.0000
6:16250279:TCTA:T	acceptor_loss	1.0000
6:16250280:CTA:C	acceptor_loss	1.0000
6:16250282:A:AG	acceptor_gain	1.0000
6:16250282:A:AT	acceptor_loss	1.0000
6:16250283:G:GG	acceptor_gain	1.0000
6:16250283:GC:G	acceptor_gain	1.0000
6:16250283:GCA:G	acceptor_gain	1.0000
6:16250363:TGCAG:T	donor_loss	1.0000
6:16250364:GCAGG:G	donor_loss	1.0000
6:16250365:CAG:C	donor_loss	1.0000
6:16250366:AG:A	donor_loss	1.0000
6:16250367:GGTAC:G	donor_loss	1.0000
6:16250368:GTACG:G	donor_loss	1.0000

AlphaMissense

2265 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:16278834:A:C	S200R	1.000
6:16278836:T:A	S200R	1.000
6:16278836:T:G	S200R	1.000
6:16285797:G:A	G220E	1.000
6:16246916:C:A	N54K	0.999
6:16246916:C:G	N54K	0.999
6:16254574:A:C	S102R	0.999
6:16254576:T:A	S102R	0.999
6:16254576:T:G	S102R	0.999
6:16254651:C:G	C127W	0.999
6:16254667:G:T	G133W	0.999
6:16254668:G:A	G133E	0.999
6:16274418:G:T	G157W	0.999
6:16274419:G:A	G157E	0.999
6:16274419:G:T	G157V	0.999
6:16274423:C:A	N158K	0.999
6:16274423:C:G	N158K	0.999
6:16274452:T:C	L168P	0.999
6:16274480:A:C	K177N	0.999
6:16274480:A:T	K177N	0.999
6:16274491:G:A	G181E	0.999
6:16278792:T:C	C186R	0.999
6:16278794:C:G	C186W	0.999
6:16278814:G:A	G193E	0.999
6:16278819:G:A	G195R	0.999
6:16278819:G:C	G195R	0.999
6:16278820:G:A	G195E	0.999
6:16278838:C:A	A201D	0.999
6:16278849:T:C	C205R	0.999
6:16278851:T:G	C205W	0.999

dbSNP variants (sampled 300 via entrez): RS1000010469 (6:16266499 C>G,T), RS1000040631 (6:16245920 C>T), RS1000062849 (6:16266299 G>A), RS1000170012 (6:16274304 G>T), RS1000177546 (6:16269669 T>C), RS1000215132 (6:16242545 T>C), RS1000304075 (6:16263096 T>A,G), RS1000319529 (6:16276243 C>A), RS1000325570 (6:16237209 C>T), RS1000467737 (6:16261178 C>T), RS1000482108 (6:16281853 G>A), RS1000552939 (6:16292091 A>G), RS1000603296 (6:16284366 T>A), RS1000653111 (6:16288933 C>T), RS1000658204 (6:16274700 G>A)

Disease associations

OMIM: gene MIM:139265 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

53 associations (top):

Study	Trait	p-value
GCST000807_11	LDL cholesterol	2.000000e-08
GCST001408_5	Response to statins (LDL cholesterol change)	5.000000e-07
GCST001601_4	Gambling	5.000000e-06
GCST001850_8	Major depressive disorder	1.000000e-06
GCST002500_54	QT interval	3.000000e-10
GCST004602_44	Mean corpuscular volume	4.000000e-43
GCST004605_28	Mean corpuscular hemoglobin concentration	4.000000e-27
GCST004611_86	High light scatter reticulocyte count	1.000000e-12
GCST004612_6	High light scatter reticulocyte percentage of red cells	3.000000e-15
GCST004615_28	Hemoglobin concentration	3.000000e-10
GCST004619_46	Reticulocyte fraction of red cells	6.000000e-16
GCST004619_81	Reticulocyte fraction of red cells	1.000000e-10
GCST004622_202	Reticulocyte count	3.000000e-11
GCST004622_203	Reticulocyte count	4.000000e-09
GCST004630_79	Mean corpuscular hemoglobin	2.000000e-12
GCST004630_80	Mean corpuscular hemoglobin	2.000000e-59
GCST005992_9	Mean corpuscular hemoglobin concentration	3.000000e-08
GCST005993_79	Mean corpuscular hemoglobin	4.000000e-18
GCST006011_111	Mean corpuscular volume	5.000000e-12
GCST006269_809	General cognitive ability	8.000000e-09
GCST010083_123	Hemoglobin levels	8.000000e-21
GCST010919_11	QT interval	3.000000e-06
GCST90002384_77	Hemoglobin	1.000000e-20
GCST90002385_359	High light scatter reticulocyte count	1.000000e-28
GCST90002385_360	High light scatter reticulocyte count	2.000000e-31
GCST90002385_361	High light scatter reticulocyte count	2.000000e-27
GCST90002386_126	High light scatter reticulocyte percentage of red cells	5.000000e-32
GCST90002386_149	High light scatter reticulocyte percentage of red cells	2.000000e-35
GCST90002386_150	High light scatter reticulocyte percentage of red cells	1.000000e-35
GCST90002387_318	Immature fraction of reticulocytes	2.000000e-09

EFO canonical traits (11, from GWAS)

EFO ID	Trait name
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0007804	LDL cholesterol change measurement
EFO:0004699	gambling behaviour
EFO:0004682	QT interval
EFO:0004528	mean corpuscular hemoglobin concentration
EFO:0007986	reticulocyte count
EFO:0004509	hemoglobin measurement
EFO:0004527	mean corpuscular hemoglobin
EFO:0004337	intelligence
EFO:0004305	erythrocyte count
EFO:0009188	Red cell distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation, affects expression	6
bisphenol A	decreases expression, increases expression	2
sodium arsenite	decreases expression, increases expression	2
potassium chromate(VI)	affects cotreatment, decreases expression, increases expression	2
Cadmium Chloride	increases expression, decreases expression, increases abundance	2
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
kojic acid	decreases expression	1
trichostatin A	affects expression	1
butyraldehyde	increases expression	1
tobacco tar	decreases expression	1
cupric chloride	decreases expression	1
nickel sulfate	increases expression	1
hydroquinone	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
pentanal	increases expression	1
chromium hexavalent ion	affects expression	1
entinostat	increases expression	1
Scutellaria barbata extract	decreases expression	1
(+)-JQ1 compound	increases expression	1
Erlotinib Hydrochloride	decreases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Acetaminophen	affects response to substance	1
Air Pollutants	decreases expression, increases abundance	1
Air Pollutants, Occupational	increases expression	1
Aldehydes	increases expression	1
Arbutin	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1FF	Abcam A-549 GMPR KO 1	Cancer cell line	Male
CVCL_B2MZ	Abcam A-549 GMPR KO 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.